Last $5.47 USD
Change Today +0.31 / 6.01%
Volume 101.6K
BOTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:22 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

biota pharmaceuticals inc (BOTA) Snapshot

Open
$5.19
Previous Close
$5.16
Day High
$5.50
Day Low
$5.13
52 Week High
03/6/14 - $7.07
52 Week Low
06/28/13 - $3.01
Market Cap
191.8M
Average Volume 10 Days
161.2K
EPS TTM
$-0.27
Shares Outstanding
35.1M
EX-Date
11/9/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTA PHARMACEUTICALS INC (BOTA)

Related News

No related news articles were found.

biota pharmaceuticals inc (BOTA) Related Businessweek News

No Related Businessweek News Found

biota pharmaceuticals inc (BOTA) Details

Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of anti-infective products in Australia. The company is developing oral, small molecule compounds to treat various viral and bacterial infections. Its product candidates include laninamivir octanoate, a long-acting neuraminidase inhibitor, which is in Phase II clinical trials for the treatment of influenza A and B; vapendavir, a Phase II compound that is in clinical development for the treatment of human rhinovirus infections in patients with mild to moderate asthma; and a discovery stage program focused on novel antibiotics to treat gram-positive and gram-negative bacterial infections. It is also developing an orally bioavailable preclinical compound for the treatment of respiratory syncytial virus infections in children, the elderly, and immunocompromised patients. Biota Pharmaceuticals, Inc. is headquartered in Alpharetta, Georgia.

89 Employees
Last Reported Date: 09/27/13

biota pharmaceuticals inc (BOTA) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $395.2K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $292.9K
Vice President of Human Resources
Total Annual Compensation: A$237.9K
Vice President of Research
Total Annual Compensation: A$332.3K
Vice President of Product Development and Str...
Total Annual Compensation: A$312.4K
Compensation as of Fiscal Year 2013.

biota pharmaceuticals inc (BOTA) Key Developments

Biota Pharmaceuticals, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 12:30 PM

Biota Pharmaceuticals, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 12:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Russell H. Plumb, Chief Executive Officer, President, Principal Financial Officer and Director.

Biota Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2013

Biota Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended December 31, 2013. For the quarter, the company has posted net loss of $100,000, or $0 per share, compared to a net income of $4.6 million, or $0.16 per share, for the same quarter ended December 31, 2012. Total revenue was $18.5 million, compared to $10.4 million for the same quarter ended December 31, 2012. Net loss for the six months ended December 31, 2013 was $4 million, or $0.14 loss per share, compared to a net loss of $2.6 million, or $0.09 loss per share, for the same period ended December 31, 2012. Total revenue for the six months ended December 31, 2013 was $30.8 million, compared to $11.8 million for the same period ended December 31, 2012.

Biota Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Month Periods Ended December 31, 2013

Biota Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six month periods ended December 31, 2013. For the quarter, the company reported total revenue of $18.5 million against $10.4 million a year ago. Loss from operations was $0.1 million against $7.8 million a year ago. Loss before tax was $0.1 million against income before tax of $4.6 million a year ago. Net loss was $0.1 million or $0.00 per diluted share against net income of $4.6 million $0.16 per diluted share a year ago. For the six months, the company reported total revenue of $30.8 million against $11.8 million a year ago. Loss from operations was $4.2 million against $15.7 million a year ago. Loss before tax was $4.1 million against income before tax of $2.7 million a year ago. Net loss was $4.0 million or $0.14 per diluted share against $2.6 million $0.09 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOTA:US $5.47 USD +0.31

BOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Roche Holding AG SFr.254.90 CHF +0.70
View Industry Companies
 

Industry Analysis

BOTA

Industry Average

Valuation BOTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 0.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTA PHARMACEUTICALS INC, please visit www.biota.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.